Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
This study has been completed.
Study NCT00759135   Information provided by Nymox Corporation

First Received on September 23, 2008.   Last Updated on June 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Benign Prostatic Hyperplasia (BPH)
Enlarged Prostate
Additional conditions recognized in this trial
Hyperplasia
Prostatic Hyperplasia
More general conditions related to this trial
Genital Diseases, Male
Pathologic Processes
Prostatic Diseases
Interventions listed in this trial
2.5 mg NX-1207
0.125 mg NX-1207
finasteride
More general drug interventions related to this trial
5-alpha Reductase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sponsors listed in this trial
Nymox Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services